University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL

Natalie Galanina, Sonali M. Smith, Chuanhong Liao, Adam Petrich, Bernadette Libao, Ronald Gartenhaus, Jason R. Westin, Kenneth S. Cohen, James A. Knost, Walter M. Stadler, Austin Doyle, Theodore Karrison, Leo I. Gordon, Andrew M. Evens

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL'. Together they form a unique fingerprint.